GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardio Diagnostics Holdings Inc (NAS:CDIO) » Definitions » Pre-Tax Income

CDIO (Cardio Diagnostics Holdings) Pre-Tax Income : $-8.38 Mil (TTM As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Cardio Diagnostics Holdings Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. Cardio Diagnostics Holdings's pretax income for the three months ended in Dec. 2024 was $-1.52 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2024 was $-8.38 Mil. Cardio Diagnostics Holdings's pretax margin was -30,380.00%.

During the past 5 years, Cardio Diagnostics Holdings's highest Pretax Margin was -23288.89%. The lowest was -466100.00%. And the median was -55638.24%.


Cardio Diagnostics Holdings Pre-Tax Income Historical Data

The historical data trend for Cardio Diagnostics Holdings's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardio Diagnostics Holdings Pre-Tax Income Chart

Cardio Diagnostics Holdings Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Pre-Tax Income
-0.61 -0.62 -4.66 -8.38 -8.38

Cardio Diagnostics Holdings Quarterly Data
Dec20 Mar21 Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Pre-Tax Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.39 -4.16 -1.29 -1.41 -1.52

Competitive Comparison of Cardio Diagnostics Holdings's Pre-Tax Income

For the Biotechnology subindustry, Cardio Diagnostics Holdings's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardio Diagnostics Holdings's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardio Diagnostics Holdings's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where Cardio Diagnostics Holdings's Pre-Tax Income falls into.


;
;

Cardio Diagnostics Holdings Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

Cardio Diagnostics Holdings's Pretax Income for the fiscal year that ended in Dec. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-8.366+0+-0.019+0.001+0.0010000000000012
=-8.38

Cardio Diagnostics Holdings's Pretax Income for the quarter that ended in Dec. 2024 is calculated as

Pretax Income=Operating Income+Non Operating Income+Interest Expense+Interest Income+Other
=-1.516+0+-0.003+0+0
=-1.52

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.38 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardio Diagnostics Holdings  (NAS:CDIO) Pre-Tax Income Explanation

Cardio Diagnostics Holdings's Pretax Margin for the quarter that ended in Dec. 2024 is calculated as

Pretax Margin=Pretax Income/Revenue
=-1.519/0.005
=-30,380.00%

During the past 5 years, Cardio Diagnostics Holdings's highest Pretax Margin was -23288.89%. The lowest was -466100.00%. And the median was -55638.24%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cardio Diagnostics Holdings Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of Cardio Diagnostics Holdings's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Cardio Diagnostics Holdings Business Description

Traded in Other Exchanges
N/A
Address
311 West Superior Street, Suite 444, Chicago, IL, USA, 60654
Cardio Diagnostics Holdings Inc is a medical technology company focused on developing and commercializing epigenetics-based clinical tests for cardiovascular diseases. The company offers three AI-powered solutions for the risk assessment, detection, management, and monitoring of coronary heart diseases. These solutions are Epi+Gen CHD, a symptomatic CHD risk assessment clinical blood test targeting CHD events; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform coupled to the Epi+Gen CHD and PrecisionCHD tests that provide personalized insights by linking the epigenetic and genetic biomarkers evaluated by these tests to the drivers of coronary heart disease.
Executives
Robert Philibert director, 10 percent owner, officer: Chief Medical Officer 400 N. ABERDEEN, SUITE 900, CHICAGO IL 60642
Timur Dogan officer: Chief Technology Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Meeshanthini Dogan director, 10 percent owner, officer: Chief Executive Officer 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Warren Hosseinion director C/O 1668 S. GARFIELD AVENUE, 2ND FLOOR, ALHAMBRA CA 91801
Elisa V Luqman officer: Chief Financial Officer 37 HARRISON DRIVE, NORTHPORT NY 11768
Khullani Abdullahi officer: VP of Revenue and Strategy 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Brandon Sim director C/O APOLLO MEDICAL HOLDINGS, INC., 1668 S. GARFIELD AVENUE, 3RD FLOOR, ALHAMBRA CA 91801
James Intrater director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Oded Levy director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Stanley K. Lau director C/O CARDIO DIAGNOSTICS HOLDINGS INC., 400 N. ABERDEEN ST., SUITE 900, CHICAGO IL 60642
Bd Holding, Inc. 10 percent owner 15 PROSPECT PLACE, IOWA CITY IA 52246
Jonathan Intrater officer: CEO 223 PALMER STREET, PALMER MA 01069
Allan Liu director 1600 PARKWOOD CIRCLE, STE 200, ATLANTA GA 30339-2119
Loren Mortman director 207 EAST 74TH STREET, APARTMENT 10F, NEW YORK NY 10021
Mana Capital Llc 10 percent owner 8 THE GREEN, SUITE A, DOVER DE 19901

Cardio Diagnostics Holdings Headlines

From GuruFocus